Clinical trial
SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A…
NCT00486369 · Nordic Bioscience A/S, Industry · Completed
Key facts
| NCT number | NCT00486369 |
|---|---|
| Title | SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study |
| Official title | SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study. |
| Lead sponsor | Nordic Bioscience A/S, Industry |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Osteoarthritis |
| Intervention type | Drug |
| Interventions | Oral salmon calcitonin |
| Start date | Jan 1, 2007 |
| First posted | Jun 14, 2007 |
| Last update posted | Jun 14, 2007 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: